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Demand for liver transplantation continues to exceed
donor organ supply. Comparing recipient survival to
that of comparable candidates without a transplant
can improve understanding of transplant survival ben-
efit. Waiting list and post-transplant mortality was
studied among a cohort of 12 996 adult patients placed
on the waiting list between 2001 and 2003. Time-
dependent Cox regression models were fitted to de-
termine relative mortality rates for candidates and re-
cipients. Overall, deceased donor transplant recipients
had a 79% lower mortality risk than candidates (HR =
0.21; p < 0.001). At Model for End-stage Liver Disease
(MELD) 18–20, mortality risk was 38% lower (p < 0.01)
among recipients compared to candidates. Survival
benefit increased with increasing MELD score; at the
maximum score of 40, recipient mortality risk was 96%
lower than that for candidates (p < 0.001). In contrast,
at lower MELD scores, recipient mortality risk during
the first post-transplant year was much higher than
for candidates (HR = 3.64 at MELD 6–11, HR = 2.35 at
MELD 12–14; both p < 0.001). Liver transplant survival
benefit at 1 year is concentrated among patients at
higher risk of pre-transplant death. Futile transplants
among severely ill patients are not identified under cur-
rent practice. With 1 year post-transplant follow-up,
patients at lower risk of pre-transplant death do not
have a demonstrable survival benefit from liver trans-
plant.
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Introduction
Liver transplantation has altered the natural history of end-
stage liver disease and is now considered the preferred
therapy for a wide range of previously fatal chronic hep-
atic diseases. Optimal timing of liver transplantation in the
course of disease is desirable to avoid harm from interven-
ing too early and futility from transplanting too late. Unfor-
tunately, little is known about the most appropriate time
in the course of chronic liver disease to offer a transplant
for the majority of patients, with the exception of primary
biliary cirrhosis and other cholestatic disorders (1–3). Ap-
propriate timing is especially important because of the un-
certain availability of a donor organ engendered by the im-
balance between the size of the pool of suitable recipients
and the number of available deceased donors (4).
Given the severe shortage of donor organs, there is a need
to identify which patients derive significant survival benefit
from transplantation and which do not. As early as 1992,
Delmonico et al. noted that assessment of outcome should
be a component of allocation policy so that futile trans-
plants could be avoided (5), and a recent report continued to
support this view (6). To date, however, only pre-transplant
mortality risk has been incorporated into liver allocation pol-
icy. The most recent change in liver allocation policy in the
United States, by which candidates are ranked according
to a more highly stratified index of pre-transplant mortality
(7), continues to offer donor livers on this basis.
Comparisons of mortality risk among transplant recipients
to mortality risk among listed transplant candidates with
chronic end-stage renal disease, matching on time since
initial listing, have been used to assess transplant survival
benefit (8). This approach avoids inappropriate compar-
isons to the entire population of patients with end-stage
disease, only a small fraction of whom are suitable candi-
dates to be listed for transplantation. Registered transplant
candidates who have already entered the transplant path-
way constitute the best comparison group to transplant
recipients.
In the field of renal transplantation, no distinctions are
drawn among candidates based on medical urgency when
allocation priority for deceased donor organs is being con-
sidered. This makes assessment of survival benefit more
straightforward (8). In contrast, liver transplant allocation is
based on the severity of the underlying disease necessitat-
ing hepatic replacement. Specifically, the current allocation
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scheme for candidates with chronic end-stage liver disease
utilizes a measure of each patient’s pre-transplant mortality
risk that is calculated based on laboratory values of serum
bilirubin, international normalized ratio of prothrombin time
and serum creatinine. The score is derived from published
data on the Model for End-stage Liver Disease (MELD),
which predicts 3-month mortality risk for adult cirrhotics
undergoing transjugular intra-hepatic portosystemic shunt
procedures as well as other chronic liver disease popula-
tions and liver transplant candidates (9–11). A similar sys-
tem (PELD) has been developed for pediatric candidates
(12).
The tacit assumption that liver transplantation provides a
large differential between waiting list mortality risk and
post-transplant mortality risk for candidates at all MELD
levels has not been previously tested at the national level.
In this article, we use data from all liver transplant cen-
ters in the United States to examine the survival benefit
attributable to liver transplantation, with a focus on adult
patients with chronic liver disease at the low and high ends
of the pre-transplant risk spectrum.
Methods
Data sources
This study used data from the Scientific Registry of Transplant Recipients
(SRTR) regarding access to transplantation, waiting list mortality and post-
transplant graft and patient survival, among all listed candidates and trans-
plant recipients in the United States submitted by the members of the Organ
Procurement and Transplantation Network (OPTN), and supplemented by
mortality information from the Social Security Death Master File (13–15).
MELD-based allocation system
The national system for liver allocation operates according to a set of nested
rules (16). Donor livers are first offered to candidates with acute liver failure
or immediate post-transplant graft failure (Status 1). After Status 1, organs
are allocated to candidates with chronic liver disease wait-listed at transplant
centers within the donor’s organ procurement organization (OPO) service
area in descending MELD or PELD order, next to candidates in other OPOs
in the region, and finally to candidates outside the region. MELD or PELD
score data must be submitted periodically, with updates at more frequent
intervals required at higher MELD or PELD scores (16). Regional review
boards may consider requests for assigned (rather than calculated) MELD
or PELD scores.
Study population
The study population included patients 18 years of age and older with an
initial date of registration for deceased donor liver transplantation between
September 2001 and June 2003 (n = 12 996). The start of the study cor-
responded to the initial date of mandatory submission of the three compo-
nents of the MELD score. Patients were followed to the earliest of death,
loss to follow-up or the end of the observation period on June 30, 2003;
post-transplant follow-up was a maximum of 1 year. Status 1 candidates
were excluded (n = 626). Candidates with a diagnosis of hepatocellular car-
cinoma were excluded, since an arbitrary MELD score is assigned to such
patients at listing. Patients who had MELD exception scores approved for
use in lieu of calculated scores were censored at the date the exception
score was granted (n = 1380). Since the study objective related to deceased
donor transplantation, patient survival was also censored at the date of living
donor liver transplant (n = 242).
Changes in calculated MELD scores for patients with chronic liver disease
were tracked. A total of 67 056 MELD scores was used for the analysis.
Among the 12 996 patients in the study, 12 138 had more than one recorded
MELD score.
Analytic approach
Patients contributed follow-up time to the candidate group before transplant
and to the transplant group if and when they received a deceased donor
liver transplant, and thereafter. Patients were censored at removal from the
candidate pool, if removal was due to patient recovery (n = 120). Transplant
recipients who experienced graft failure (with or without retransplantation)
were not censored. Waiting list patients were classified based on their cur-
rent MELD score. Waiting candidates contributed follow-up time at risk ac-
cording to their most recent MELD score and could therefore accrue periods
of follow-up time in multiple categories if their MELD score changed. Trans-
plant recipients were classified based on their final pre-transplant MELD
score.
Unadjusted mortality rates were computed as the ratio of risk category-
specific deaths per 1000 patient years of follow-up. Cox regression models
were used to compare mortality for waiting list candidates and transplant re-
cipients, at equal duration since wait-listing, adjusted for age, sex, race, diag-
nosis, education, insurance coverage and updated (time-dependent) MELD
score and MELD (17). We computed MELD, a measure of how rapidly
the candidate’s MELD is changing, as the change in MELD score divided
by the length of the time interval between reported dates of change.
The covariate-adjusted hazard ratio for mortality risk of transplant compared
to mortality risk on the waiting list was estimated for the study population
as a whole. Separate models were also fitted for several MELD subgroups.
Lastly, non-proportional (piecewise proportional hazards) Cox models were
used to estimate mortality hazard ratios for post-transplant follow-up time
windows of 0–7, 8–30 and 31–365 days compared to corresponding waiting
list candidates.
Results
Characteristics of the study population at the time of place-
ment on the waiting list are shown in Table 1. Just over
60% of candidates were aged 50 or older at listing. Males
made up 64% of the cohort and over 87% of the candidates
were white. Hispanic ethnicity was noted for 14.6% of
candidates. The most common diagnosis group was non-
cholestatic cirrhosis; hepatitis C cirrhosis was the most
common individual diagnosis (32%).
At the time of listing, more than one-half of candidates had
a MELD score less than 15 and 9% had a score above 26
(Figure 1). The distribution of MELD scores at the time of
transplant showed a shift toward higher scores (more
than 25% above 26), although 24% of transplants were
performed at MELD scores less than 15 (Figure 2). The
proportion of transplant recipients with a MELD score at
transplant less than 12 was 10%.
A total of 1538 pre-transplant deaths and 255 post-
transplant deaths were observed (Table 2). The unadjusted
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Non-Hispanic 11 096 85.4
Diagnosis
Hepatitis C cirrhosis 4189 32.2
Alcoholic cirrhosis 2044 15.7
Hepatitis B cirrhosis 534 4.1
Non-cholestatic cirrhosis (other) 2644 20.3
Primary sclerosing cholangitis 586 4.5
Primary biliary cirrhosis 539 4.2
Cholestatic cirrhosis (other) 30 0.2
Others 2430 18.7
Education







waiting list mortality rate was 217 deaths per 1000 pa-
tient years, compared to 184 deaths per 1000 patient
years among transplant recipients. There was approxi-
mately 300-fold range of waiting list mortality rates be-
tween patients with MELD scores 6–11 and those with
MELD scores of 40 and higher. Patients with MELD scores
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Figure 1: Distribution of MELD
scores at initial placement on wait-
ing list.
rates that were more than 50% greater than that of the
MELD 6–11 category.
Overall covariate-adjusted mortality risk from the Cox re-
gression model was 79% lower for liver transplant recip-
ients compared to candidates on the waiting list (hazard
ratio = 0.21; 95% confidence interval = 0.18–0.24; p <
0.001), indicating a significant survival benefit of liver trans-
plantation. However, the salutary effect of transplantation
on survival varied across the range of MELD scores (Fig-
ure 3). With 1 year of available post-transplant follow-up,
MELD category 15–17 represented a transition point. Post-
transplant mortality risk was more than three times higher
than waiting list mortality for MELD scores 6–11 (hazard
ratio = 3.64; 95% confidence interval = 2.23–5.95; p <
0.001). The hazard ratio was also greater than 1.0 among
patients with MELD 12–14 (hazard ratio = 2.35; 95% con-
fidence interval 1.48–3.76; p < 0.001). Conversely, signif-
icant transplant survival benefit was observed at MELD
scores 18 and higher, and the magnitude of transplant ben-
efit increased with increasing MELD score (Figure 3).
The majority of patients with low MELD scores showed lit-
tle to no progression over time. Among 1861 patients who
were initially listed in the MELD (6–11) category and had at
least 1 year of follow-up, 75.9% remained in that category
1 year later. Less than 5% progressed into a MELD score
category associated with significant survival benefit.
Some patients were assigned a MELD score of 40 by the
OPTN even though their calculated score was higher, be-
cause current allocation policy caps the score. Among 570
patients with a capped MELD score, 469 (82%) had an ac-
tual calculated MELD greater than 40 (range: 41–68). A sep-
arate Cox regression model for patients with MELD scores
greater than or equal to 40 was fitted using the actual cal-
culated MELD scores showed that mortality risk (and thus
transplant benefit) for transplant recipients among these
most ill patients remained stable (hazard ratio = 1.00; 95%
confidence interval 0.89–1.11).
The observed contrast between post-transplant and wait-
ing list mortality varied strongly across the follow-up period
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Figure 3: Comparison of mortal-
ity risk expressed as hazard ra-
tio by MELD score for recipients
of liver transplants compared to
candidates on the liver transplant
waiting list.
Table 2: Unadjusted waiting list and transplant mortality rates by MELD category
Waiting list Transplant (1 year follow-up)
MELD Deaths Patient years (PY) Rate per 1000 PY Deaths Patient years (PY) Rate per 1000 PY
6–11 130 2901 44.8 19 116 163.3
12–14 96 1830 52.5 23 180 127.4
15–17 181 1237 146.4 38 231 164.7
18–20 150 552 271.9 33 190 174.1
21–23 142 276 514.9 31 174 178.4
24–26 105 125 840.7 21 119 176.9
27–29 99 60 1663.8 18 92 195.9
30–39 348 75 4634.1 54 220 245.5
40∗ 287 22 13 152.7 18 68 264.6
Total 538 7078 217.3 255 1390 183.5
∗Includes patients whose MELD score was capped at 40.
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Table 3: Covariate-adjusted mortality hazard ratios (transplant: waiting list) by MELD score category and post-transplant follow-up time
Days post-transplant
0–7 days 8–30 days 31–365 days
MELD Category HR∗ (95% CI)† p-value HR∗ (95% CI)† p-value HR∗ (95% CI)† p-value
6–11 33.03 (13.74, 79.22) <0.001 9.26 (3.34, 25.69) <0.001 1.79 (0.89, 3.59) 0.10
12–14 27.91 (11.81, 66.00) <0.001 1.24 (0.17, 8.96) 0.83 1.76 (1.01, 3.06) 0.04
15–17 5.86 (2.57, 13.35) <0.001 2.52 (1.23, 5.16) 0.01 0.82 (0.52, 1.28) 0.37
18–20 2.83 (1.04, 7.72) 0.04 1.13 (0.46, 2.78) 0.79 0.48 (0.31, 0.76) 0.002
21–29 1.65 (1.00, 2.73) 0.05 0.50 (0.29, 0.86) 0.01 0.15 (0.11, 0.22) <0.001
30–39 0.20 (0.09, 0.43) <0.001 0.09 (0.05, 0.17) <0.001 0.06 (0.04, 0.08) <0.001
40‡ 0.11 (0.04, 0.26) <0.001 0.04 (0.01, 0.10) <0.001 0.02 (0.01, 0.03) <0.001
∗Hazard ratio for post-transplant mortality risk based on MELD score at transplant compared to wait-listing while at the same MELD
score.
†95% confidence interval.
‡Includes patients whose MELD score was capped at 40.
(Table 3). Generally, post-transplant mortality within each
MELD category decreased as follow-up time increased.
At MELD 6–11, post-transplant mortality was significantly
higher than waiting list mortality for the first post-transplant
month, while recipients transplanted at MELD scores of 30
and higher had a significant survival benefit within the first
post-transplant week. Recipients with MELD scores 21–
29 demonstrated significant survival benefit after the first
post-transplant week.
Discussion
The ability of MELD to predict mortality in patients with
chronic liver disease has contributed to the evolution of
liver allocation policy in the United States (9,10). It is es-
tablished that MELD is an important predictor of waiting
list mortality (11,17,18), and several authors have recently
reported that MELD is predictive of post-transplant mor-
tality risk (6,19). One study failed to show a significant
relationship between pre-transplant MELD score and post-
transplant outcome, but this report was from a single-
center study with limited sample size (20). In our study,
we found approximately a 300-fold range of mortality risk
across the MELD spectrum for patients on the waiting list,
and a 1.5-fold range for post-transplant mortality risk. The
availability of serial MELD data allows detailed analyses
of the survival benefit of liver transplantation to be per-
formed, comparing waiting list and post-transplant mortal-
ity risk within MELD categories.
This study demonstrates significant overall liver transplant
survival benefit for patients with chronic liver disease,
and provides important validation of the procedure as life-
saving therapy. Deceased donor liver transplant recipients
have an overall covariate-adjusted mortality risk that is less
than one-quarter that of patients on the waiting list; this
finding holds with and without the inclusion of MELD as
a covariate.
Liver transplant survival benefit is not evenly distributed
across the range of MELD scores. This is particularly use-
ful in considerations of organ allocation, where relative sur-
vival benefit among a group of candidates must be deter-
mined. On the other hand, the physician and candidate
faced with a decision regarding wait-listing or acceptance
of an offer of a donor liver must consider whether that
particular candidate’s expected lifetime with a transplant,
given their current medical condition as reflected by their
MELD score or other factors, is predicted to exceed that
expected if the transplant is not performed. Our analyses
facilitate discussion of both these issues.
At MELD scores 18 and higher, significant and progres-
sively increasing survival benefit was demonstrated. At
the highest end of the risk spectrum, there does not ap-
pear to be a MELD score above which transplantation is
clearly futile. In a supplementary analysis, a Cox model
fitted to the subgroup of patients with uncapped MELD
scores of 40 and greater showed that the mortality hazard
ratio continued to favor transplant. However, the rate of
transfer to inactive status on the waiting list increases at
higher MELD scores (data not shown), suggesting that ef-
fective clinical decision making and recipient selection is at
work among these sick candidates. In fact, at the highest
end of the MELD scale, waiting list mortality risk is ex-
tremely high, whereas post-transplant mortality risk rises
much more gradually. These relationships help to explain
the progressively higher benefit of liver transplantation as
MELD increases.
In contrast to the findings for patients with high MELD
scores, post-transplant mortality risk for the nearly one in
four recipients who received liver transplants for chronic
liver disease at a MELD score less than 15 was significantly
higher than for comparable candidates on the waiting list.
This suggests that liver transplant is more hazardous than
remaining on the waiting list in such cases, based on 1
year of post-transplant follow-up. With longer follow-up, a
survival benefit for low MELD patients may eventually be
demonstrated, but in relative terms that benefit is likely to
be of lesser magnitude than for those with higher MELD
scores. Moreover, three-quarters of patients with MELD
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scores between 6 and 11 at listing continue to have MELD
scores in that range 1 year later, suggesting that the risk
of rapid progression is low.
On initial examination, it may be surprising that so many
patients with low MELD scores receive liver transplants,
as the current allocation policy is intended to direct donor
livers to high MELD score candidates. Two related factors
explain this finding. First, the MELD scores of the highest
ranking candidate in each OPO vary considerably, reflecting
the marked heterogeneity in the acuity of liver transplant
candidates across the United States (21). Second, organs
are offered to chronic liver disease candidates in descend-
ing MELD score order within the OPO service area where
the donor is identified before they are offered to candidates
outside that OPO. Thus, one-half of all livers are offered
first to candidates with MELD scores less than 18 (data
not shown). These factors collectively lead to the current
situation in which over 40% of all liver transplants are given
to patients with MELD scores below 18.
This study has implications for liver allocation policy in the
United States. The current ordering of liver transplant can-
didates with chronic liver disease appears to be subopti-
mal. Distribution of donor livers to candidates with higher
MELD scores in a larger initial geographic unit than the
OPO, extending to the regional level, would simultane-
ously steer a higher proportion of scarce organs to patients
likely to benefit from them and reduce the probability of
transplant for those with less likelihood of benefit. The lat-
ter element is important, given that candidates with very
low MELD scores cannot yet be shown to benefit from a
transplant, and may even be harmed by one. The Board of
Directors of the OPTN recently approved such a modifica-
tion to the national allocation system for deceased donor
livers in the United States (22).
Separately, establishment of a minimum MELD score for
placement on the waiting list would be a more direct
method of reducing the proportion of transplants given to
patients with low MELD scores. Selection of a minimum
listing MELD score needs to be informed by several con-
siderations. With sufficiently long follow-up, a subset of
patients with MELD scores below 18 may ultimately be
shown to derive significant benefit. It may be imprudent,
therefore, to suggest a minimum MELD score for listing
that is too close to the currently calculated transplant ben-
efit transition range of 15–17. On the downside, if patients
were no longer able to be listed for transplant at low MELD
scores, it might be more difficult for transplant physicians
to study the course of end-stage liver disease. It has been
suggested that transplant teams might not be permitted
by third-party payers to follow patients referred for trans-
plantation unless they are placed on the waiting list. These
considerations must be weighed against the potential harm
of doing a liver transplant that does not significantly pro-
long the life of the recipient, particularly as candidates with
higher MELD scores and greater expected benefit are avail-
able on the waiting list. Reevaluation of individual benefit
calculations will be useful when longer follow-up becomes
available, although it will not likely change the ordering of
benefit by MELD.
In summary, our analysis adds important data to the con-
tinuing evolution in organ allocation policy. These results
suggest that transplants are being performed for some
candidates who have a higher risk of dying from the trans-
plant procedure than they have of dying from their under-
lying liver disease. Rather than relying solely on the risk
of pre-transplant death, the survival benefit among candi-
dates should be considered as a component of allocation
policy in order to direct organs to those most likely to bene-
fit from the procedure. The current practice of transplanting
substantial number of patients at low MELD scores, with
associated lack of demonstrable transplant benefit, should
be carefully reconsidered.
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